AZ-Glenmark Saxagliptin Case Heads For Settlement?
This article was originally published in Scrip
Executive Summary
More than a year after AstraZeneca PLC. hauled Glenmark to court over intellectual property rights issues concerning its dipeptidyl peptidase-4 (DPP-4) inhibitor for diabetes, Onglyza (saxagliptin), in India, there are some signs of a potential thaw in the legal tussle.